Key Takeaways
- The FDA advisory committee delivered a 7-2 vote indicating Galleri’s benefits exceed its potential risks.
- Safety received unanimous approval with a 10-0 vote, while effectiveness passed 6-4.
- Shares of Grail surged 36% throughout the week, trading around $108.
- Canaccord Genuity maintained its Buy recommendation and increased its price forecast after the hearing.
- Final FDA clearance may come in the coming months.
Shares of Grail (GRAL) are hovering near $108 following a pivotal week in which an FDA advisory committee endorsed the company’s Galleri multicancer blood screening test. The biotech firm saw its stock price soar 36% over the past week, with the majority of gains materializing in the days leading up to and following Wednesday’s panel meeting.
During Wednesday’s session, the Molecular and Clinical Genetics Devices Panel convened to evaluate Galleri’s merits. Panel members delivered a 7-2 decision, with one abstaining vote, concluding that the screening test’s advantages outweigh its potential drawbacks.
Safety concerns were not an issue, as evidenced by the panel’s unanimous 10-0 endorsement. The effectiveness determination proved more contentious, with a narrower 6-4 approval.
Trading activity for Grail stock remained suspended throughout Wednesday’s panel deliberations. The stock had already experienced significant appreciation following the publication of encouraging briefing materials on Monday.
While final FDA clearance remains pending, the hearing’s positive tone suggests approval is probable. Market analysts anticipate a regulatory decision within the coming months.
Understanding Galleri’s Functionality
The Galleri test analyzes blood samples for circulating DNA fragments that exhibit cancer cell markers. It determines whether a cancer signal exists somewhere in the patient’s body and provides an estimate of the signal’s origin location.
Clinical study data demonstrates Galleri’s ability to identify cancers lacking established screening protocols, such as ovarian and pancreatic malignancies. While false positives occur infrequently, the test successfully detects cancer approximately 50% of the time when malignancy is present.
This detection performance is competitive with established diagnostic tools like mammography. Grail emphasizes that patients should continue utilizing conventional single-cancer screening methods in conjunction with Galleri, rather than as a replacement.
However, one study outcome presents challenges. The NHS-Galleri trial conducted in the United Kingdom failed to demonstrate a reduction in Stage IV cancer diagnoses one year post-screening.
Several panel members cited this data gap as a source of uncertainty regarding Galleri’s impact on mortality rates. It’s worth noting that numerous widely adopted screening technologies, including colonoscopy, gained acceptance prior to the availability of long-term survival evidence.
Revenue Projections and Expert Analysis
Currently, Grail markets Galleri at a retail price of $950, though insurance reimbursement remains limited. The company generated approximately $150 million in revenue last year, with current year forecasts suggesting $180 million.
Mizuho analyst Bradley Bowers anticipates substantially higher growth following regulatory approval. He referenced comparable cancer screening products, such as Cologuard and Guardant Health’s Shield test, both of which experienced revenue doubling during their initial launch periods.
Federal legislation has already mandated Medicare evaluation of coverage for tests like Galleri upon FDA authorization. UBS analyst Doug Schenkel projects that Medicare reimbursement beginning in 2029 could contribute approximately $300 million to Grail’s annual revenue the subsequent year, potentially driving total sales toward the $1 billion threshold.
On Wednesday, Canaccord Genuity reaffirmed its Buy stance on Grail and characterized the hearing outcome as exceeding expectations. The firm interprets the panel’s risk-benefit assessment as a robust indicator of eventual regulatory clearance.
Grail’s current market capitalization stands at $4.3 billion, representing roughly 19 times projected sales for the upcoming year. This valuation suggests the market has already factored in a substantial probability of approval.
According to InvestingPro data, the stock is trading above the platform’s calculated fair value, with RSI indicators suggesting overbought territory following the recent rally. Profitability is not anticipated for the current fiscal year.
During its latest quarterly report, Grail disclosed revenue of $44.7 million, surpassing the analyst consensus of $43.2 million, while posting a per-share loss of $2.56. Canaccord has scheduled a Friday webcast featuring two oncology screening specialists to discuss the panel’s conclusions and future implications.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
